Healthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pill ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.